OTC PDE5 Inhibitor Qualification System for Safe Patient Access
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge lies in making cGMP-specific phosphodiesterase 5 (PDE5) inhibitors, used to treat erectile dysfunction, available over-the-counter while ensuring safe and responsible use, as current prescription requirements limit access and there are concerns about inappropriate patient selection and medication use.
Innovation Solution
A system and method that qualify human subjects for over-the-counter delivery of PDE5 inhibitors through surveys and filters, where survey results are run against contraindications and risk factors, providing warnings and ensuring proper acknowledgment before drug dispensing, to ensure safe use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If PDE5 inhibitors are made available over-the-counter, then accessibility and availability of treatment is improved, but patient safety and appropriate drug selection deteriorate
Solution Approach 1:
The system performs preliminary qualification of patients through automated surveys and health questionnaires before allowing OTC purchase of PDE5 inhibitors. This pre-screening process identifies contraindications and ensures appropriate patient selection, thereby maintaining safety while enabling OTC accessibility.
Solution Approach 2:
An automated computer-based qualification system acts as an intermediary between the patient and the medication. This intermediary performs health assessments, checks for contraindications, and determines eligibility before the patient can access the drug, thus ensuring safety without requiring a prescription.
2Productivity
If prescription requirements are removed, then treatment accessibility is improved, but risk of misuse and adverse effects increases
Solution Approach 1:
Patients complete self-administered health questionnaires and surveys to qualify themselves for PDE5 inhibitor use. The system processes their responses automatically to determine eligibility, enabling patients to access treatment independently while still undergoing safety screening.
Solution Approach 2:
The system provides immediate feedback to patients regarding their qualification status based on their survey responses. If contraindications are identified, the system communicates this to the patient and prevents purchase, thereby reducing misuse risk while maintaining accessibility for qualified individuals.
3Measurement precision
If automated qualification systems are implemented, then patient screening accuracy is improved, but system complexity increases
Solution Approach 1:
The manual prescription and screening process is replaced with an automated computer-based system that electronically processes patient surveys, applies qualification criteria, and determines eligibility. This substitution maintains high screening accuracy while reducing operational complexity through automation.
Solution Approach 2:
The system uses predefined parameter thresholds and criteria (e.g., age ranges, specific medical conditions, medication interactions) to automatically qualify or disqualify patients. By changing the screening approach from subjective clinical judgment to objective parameter-based automation, accuracy is improved while system complexity is managed through standardized algorithms.
Data Source
AI summary
A method is provided for treating erectile dysfunction in a subject in need thereof by administering a cGMP-specific phosphodiesterase 5 (PDE5) inhibitor pharmaceutical composition to a subject qualified for over-the-counter access to the PDE5 inhibitor pharmaceutical composition. In some embodiments, the PDE5 inhibitor pharmaceutical composition includes tadalafil or vardenafil.